Picture [iito] Made Without Love 650x80px
Document › Details

AstraZeneca plc. (5/8/18). "Press Release: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-sensitive Relapsed Ovarian Cancer".

Region Region EU (European Union)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 Merck & Co. Inc. (NYSE: MRK)
  Group Merck (US) (MSD) (Group)
Products Product Lynparza®
  Product 2 chemotherapeutic
Index term Index term AstraZeneca–Merck (US): cancer drugs, 201707– strategic oncology collab maximising combis of PARP + MEK inhibitors with PD-L1/PD1 medicines
Persons Person Fredrickson, David (AstraZeneca 201711 EVP Head of Oncology Business Unit)
  Person 2 Baynes, Roy (Merck(US) 201412 SVP Global Clinical Development)

Record changed: 2018-05-16


Picture [iito] Plain Stupid Simple 650x80px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top